Cerus (CERS) Long-Term Debt Repayments (2010 - 2023)

Cerus' (CERS) quarterly Long-Term Debt Repayments came in at $1.4 million in Q1 2023, up 5941.67% quarter-over-quarter from $24000.0 in Q4 2019.

Cerus (CERS) Long-Term Debt Repayments (2010 - 2023) Analysis & Trends

Cerus has disclosed Long-Term Debt Repayments across 11 years of filings, most recently posting $1.4 million for Q1 2023.

Long-Term Debt Repayments for Q1 2023 came in at $1.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $1.5 million (changed N/A YoY), and the FY2019 annual result was $31.1 million, up 23286.47% from the prior year.
Long-Term Debt Repayments came in at $1.4 million for Q1 2023 at Cerus, up from $24000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $31.0 million in Q1 2019 to a low of $24000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	1.42 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	1.00 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	-
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Cerus	496.03 Mn	416.34 Mn	27.89 Mn	-

Download Data